Company News
Now Available!|Research-Grade ActCel T Cell Activation Reagent – Free Trials for New Product
T cells play a crucial role in our immune system, and T cell therapies are breaking ground in treating challenging diseases like cancer and autoimmune disorders. A key step in T cell therapy, T cell activation, directly impacts therapeutic outcomes. That’s why we're excited to introduce our ActCel T Cell Activation Reagent (Cat. No. TL-6001-1000) — designed for gentle, efficient activation to support high cell viability and expansion.
Key Features
✔️ Safe and Effective: Gentle activation for robust cell expansion
✔️ Easy to Use: Ready-to-use format
✔️ Cost-Effective: Reliable performance with competitive pricing
Our Latest Webinar: "Understanding Autoimmune CAR-T Therapy"
Autoimmune diseases are a global health challenge, affecting nearly 10% of the population. But what if I told you there's a potential breakthrough in treating these conditions?
We're excited to share our latest webinar, " Understanding Autoimmune CAR-T Therapy," featuring Dr. Allan Zhang. In this insightful session, Dr. Zhang explores the cutting-edge of CAR-T technology and its application in autoimmune diseases, offering hope for drug-free remission.
Meet Us at the ESGCT Congress in Rome!
We are delighted to announce that T&L Biotechnology will be participating in the 31st Annual ESGCT Congress, a premier event in gene and cell therapy.
Don't miss this chance to be part of a transformative event. For more information or to set up a meeting, please contact us directly. We are excited to welcome you to our booth and discuss how T&L Biotechnology can be a valuable partner in your scientific journey.
See you in Rome!
New Product Launch | Nanoscale Sorting Magnetic Beads Weighing Heavily~
Cell therapy has developed rapidly in recent years in pharmaceutical research and development, and is a new drug development model that has shown great potential in the treatment of diseases such as cancer, infectious diseases, and autoimmune diseases.
Good News | T&L CGT Core Raw Material CD28 Monoclonal Antibody Has Completed FDA DMF Filing
Recently, Beijing T&L Biotechnology Ltd. (referred to as "T&L") successfully obtained the US FDA DMF registration for its CGT core raw material CD28 monoclonal antibody, with DMF registration number 038820.
Good News | T&L Cell Therapy Key Materials Have Been Registered with Fda Dmf, Helping Your Drug Application Process
Recently, Beijing T&L Biotechnology Ltd. (hereinafter referred to as "T&L") received a confirmation letter from the US Food and Drug Administration (hereinafter referred to as "FDA"), stating that the company's key raw materials for cell therapy drugs, CD3 monoclonal antibody, and T cell sorting activation magnetic beads, have officially completed the DMF type II filing with the US FDA.